financetom
Business
financetom
/
Business
/
Capital India Home Loan plans to double asset book to Rs 250 cr this fiscal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Capital India Home Loan plans to double asset book to Rs 250 cr this fiscal
Jun 2, 2021 6:55 AM

Mortgage player Capital India Home Loan aims to double its asset book to over Rs 250 crore by the end of the current fiscal. The housing finance company promoted by NBFC firm Capital India Finance Limited (CIFL) had a loan book of about Rs 135 crore in the financial year ended March 31, 2021. ”We have just closed the financial year and the loan book should double during the current financial year,” CIFL Chairman Harsh Kumar Bhanwala told PTI. The loan book expected to touch Rs 250 crore by March 2022, he added.

Capital India Home Loans is a new-age mortgage firm with a focus on premium loan offerings to home buyers. Talking about NBFC business, Bhanwala said, the company has changed its focus from mid-corporate to SME and priority sector lending. Despite difficulties in the economy due to COVID-19, the company has been able to rein in its non-performing assets (NPAs).

CIFL — promoted by S K Narvar — has opened 7 more offices across the country. The company is a technology-enabled SME finance platform, which partners with small and medium businesses with customised finance solutions. It is also engaged in retail finance, remittance, and payments solutions. Depending on the market condition, Bhanwala said, NBFC would be raising resources to fund business growth.

The company plans to raise up to Rs 1,000 crore by issuing debt securities. The board of directors at its meeting held last week approved raising of funds, in Indian/foreign currency, of up to Rs 1,000 crore through the issue of non-convertible debentures/bonds, medium-term notes and other debt securities.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Emerge Commerce Fourth-Quarter Loss Widens on Weaker Revenue
Emerge Commerce Fourth-Quarter Loss Widens on Weaker Revenue
Apr 29, 2024
01:24 PM EDT, 04/29/2024 (MT Newswires) -- Emerge Commerce ( EMCMF ) , an e-commerce brand portfolio, on Monday said its fourth-quarter loss widened on lower revenue. The company said it lost C$17.52 million, or C$0.14 per share in the quarter, compared with a loss of C$15.5 million, or C$0.15, in the year-prior period. Revenue fell 22% to C$6.21 million...
Complete Solaria Appoints T.J. Rodgers as CEO, Promotes Brian Wuebbels to COO
Complete Solaria Appoints T.J. Rodgers as CEO, Promotes Brian Wuebbels to COO
Apr 29, 2024
01:22 PM EDT, 04/29/2024 (MT Newswires) -- Complete Solaria ( CSLR ) said Monday it appointed Executive Chairman T.J. Rodgers as chief executive and promoted Chief Financial Officer Brian Wuebbels to chief operating officer. Rodgers will succeed current CEO Chris Lundell, who will remain on the company's board, according to Complete Solaria ( CSLR ). The company shares were up...
Looking At Exxon Mobil's Recent Unusual Options Activity
Looking At Exxon Mobil's Recent Unusual Options Activity
Apr 29, 2024
Financial giants have made a conspicuous bullish move on Exxon Mobil ( XOM ). Our analysis of options history for Exxon Mobil ( XOM ) revealed 25 unusual trades. Delving into the details, we found 60% of traders were bullish, while 28% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $226,087,...
Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says
Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says
Apr 29, 2024
01:19 PM EDT, 04/29/2024 (MT Newswires) -- Axsome Therapeutics ( AXSM ) has a strong risk/reward profile for the phase 3 readout of AXS-05, an investigational treatment for Alzheimer's disease, , Morgan Stanley said in a note Monday. The company has a high probability of success and potential for significant gains from the trial, and a downside protection from existing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved